Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta
Open accessAbstract
Background: Thyroid hormone (TH) has important functions in controlling hepatic lipid metabolism. Individuals with resistance to thyroid hormone beta (RTHβ) who harbor mutations in the THRB gene experience loss-of-function of thyroid hormone receptor beta (TRβ), which is the predominant TR isoform expressed in the liver. We hypothesized that individuals with RTHβ may have increased hepatic steatosis. Methods: Controlled attenuation parameter (CAP) was assessed in individuals harboring the R243Q mutation of the THRB gene ( n = 21) and in their wild-type (WT) first-degree relatives ( n = 22) using the ultrasound-based transient elastography (TE) device (FibroScan). All participants belonged to the same family, lived on the same small island, and were therefore exposed to similar environmental conditions. CAP measurements and blood samples were obtained after an overnight fast. The observers were blinded to the status of the patients. Results: The hepatic fat content was increased in RTHβ individuals compared with their WT relatives (CAP values of 263 ± 21 and 218.7 ± 43 dB/m, respectively, p = 0.007). The CAP values correlated with age and body mass index (BMI) (age: r = 0.55, p = 0.011; BMI: r = 0.51, p = 0.022) in the WT first-degree relatives but not in RTHβ individuals, suggesting that the defect in TRβ signaling was predominant over the effects of age and obesity. Circulating free fatty acid levels were significantly higher in RTHβ individuals (0.29 ± 0.033 vs. 0.17 ± 0.02…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with resistance to thyroid hormone, the opposite effect on intrahepatic lipid content is observed.
“Indeed, low-dose LT4 reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and metabolic (dysfunction)-associated fatty liver disease (77), whereas the opposite is observed in patients with resistance to TH (78).”
From Emerging Therapies in Hypothyroidism (2024) · cites this paper as [78]
Cites
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,831 · see citing works
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228 · see citing works
Kim, D., Kim, W., Joo, S. K., Bae, J. M., Kim, J. H., & Ahmed, A. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.08.014 · Cited by 191 · see citing works
Peeters, R. P. (2008) · Hormones · doi:10.14310/horm.2002.1111035 · Cited by 98 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Lee, E., Korf, H., & Vidal‐Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 228 · see citing works
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. (2024) · Liver international (Print) · doi:10.1111/liv.15930 · Cited by 174 · see citing works
“26 Consistent with these mouse observations, linkage studies showed that humans bearing THR-β loss- of-function variants had greater hepatic fat content on ultrasound than relatives with wild-type alleles, 27 interrupting the expected positive relationship between BMI and hepatic fat accumulation.”
BackgroundKarim, G., & Bansal, M. B. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.60 · Cited by 145 · see citing works
“In one study, patients with THR-β mutations had increased liver fat (as assessed by controlled attenuation parameters using transient elastography) compared with their unaffected family members, while controlling for body mass index.(37) All participants belonged to the same family, lived on the same small island and…”
BackgroundMetabolic Messengers: Thyroid Hormones
Sinha, R. A., & Yen, P. M. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00986-0 · Cited by 115 · see citing works
“…hypertriglyceridemia, insulin resistance, and non-alcoholic fatty liver disease, increased prevalence of attention-deficit disorder, and reduced colour vision and hearing 46,47 reflecting the important roles of THRβ1 in the adult liver and THRβ2 in the development of brain, retina, and cochlea.”
Self-citationNAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93 · see citing works
“Humans bearing loss-of-function mutations in the THRβ gene show thyroid hormone resistance [30] and a higher risk for liver steatosis [31].”
BackgroundActions of thyroid hormones and thyromimetics on the liver
Sinha, R. A., Bruinstroop, E., & Yen, P. M. (2024) · Nature reviews: Gastroenterology & hepatology · doi:10.1038/s41575-024-00991-4 · Cited by 64 · see citing works
Self-citationEarly induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression
Bruinstroop, E., Zhou, J., Tripathi, M., Yau, W. W., Boelen, A., Singh, B., & Yen, P. (2021) · bioRxiv · doi:10.1016/j.molmet.2021.101266 · Cited by 52 · see citing works
“com both hypothyroidism and thyroid hormone receptor b mutations in mice and humans increase NAFLD risk [8,9].”
BackgroundSelf-citationThyroid hormone action and liver disease, a complex interplay
Marino, L., Kim, A., Ni, B., & Celi, F. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000551 · Cited by 45 · see citing works
“[39] In the next section, we will discuss in more detail how TH is involved in hepatic lipid metabolism and in cholesterol metabolism.”
Persani, L., Rodien, P., Moran, C., Visser, W., Groeneweg, S., Peeters, R. P., Refetoff, S., Gurnell, M., Beck-Peccoz, P., & Chatterjee, K. (2024) · European Thyroid Journal · doi:10.1530/etj-24-0125 · Cited by 39 · see citing works
Self-citationEmerging Therapies in Hypothyroidism
Bianco, A. C. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-060622-101007 · Cited by 36 · see citing works
Oliveira, L. S. D., & Ritter, M. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000596 · Cited by 32 · see citing works
“[78,79]”
Polyzos, S. A., & Targher, G. (2024) · Diabetes, obesity and metabolism · doi:10.1111/dom.16117 · Cited by 31 · see citing works
“19 On the contrary, other authors supported that resistance to THs, indirectly evaluated by the calculation of the thyrotroph T4 sensitivity index, was higher in euthyroid patients with biopsy-proven MASLD and advanced fibrosis than in those without hepatic fibrosis or with minimal fibrosis.”
Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon
Byrne, C. D., Targher, G., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330596 · Cited by 30 · see citing works
“13 Preclinical studies and results in humans have, therefore, supported the importance of THR-β in hepatic steatosis and stimulated interest in developing THR-β agonists as potential treatments for MASLD.”
ResultTang, Q.-Y., Zeng, M.-J., Chen, L., & Fu, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.871100 · Cited by 30 · see citing works
Metabolic and Functional Cross Talk Between the Thyroid and Liver
Chng, C., Goh, G., & Yen, P. M. (2025) · Thyroid · doi:10.1089/thy.2025.0178 · Cited by 26 · see citing works
“75 These studies also demonstrate the critical role of THR b in the liver to maintain normal lipid metabolism and prevent the development of MASLD in humans.”
Self-citationHuang, B., Wen, W., & Ye, S.-D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1009912 · Cited by 24 · see citing works
“provided evidence that impairments in liver TRb signaling due to mutations in the THRB gene can lead to hepatic steatosis, which indicates the influence of TH on lipid metabolism in the liver (24).”
BackgroundMarschner, R., Arenhardt, F., Ribeiro, R., & Wajner, S. (2022) · Metabolites · doi:10.3390/metabo12080675 · Cited by 24 · see citing works
“In contrast, other studies found that an increase in the amount of the THR-β receptor increases the sensitivity of the liver tissue to the T3 hormone, improving mitochondrial function, β-oxidation, and slowing the progression of the disease.”
BackgroundInfluentialResmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier
Tiwari, A., Sharma, A., Kumar, H., Gupta, V., Deshpande, V., Mupparaju, J. S., Mishra, T., Bharadwaj, H. R., Dahiya, D. S., & Jain, V. (2025) · Biomedicines · doi:10.3390/biomedicines13092079 · Cited by 17 · see citing works
“Linkage studies have shown similarity in mice and humans in that humans bearing THR-B loss-of-function variants had greater hepatic fat content on ultrasound [29,36].”
Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Chui, Z. S. W., Xue, Y.-Q., & Xu, A.-M. (2024) · Medical Review · doi:10.1515/mr-2024-0007 · Cited by 18 · see citing works
“Likewise, humans bearing loss-of-function mutations in the THRB gene are at much higher risk for liver steatosis [29].”
BackgroundTargeting nuclear receptors for NASH/MASH: From bench to bedside
Sinha, R. A. (2024) · Liver Research · doi:10.1016/j.livres.2024.03.002 · Cited by 18 · see citing works
“34 In human studies, low-dose TH as well as two liver-specific THR β specific agonists VK-2809/MB-07811 and resmetirom (MGL-3196) have shown significant efficacy in resolving MASLD/MASH.”
BackgroundEffect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its Underlying Mechanisms
Ye, J., Xu, J., Wen, W., & Huang, B.-Y. (2022) · International journal of clinical practice · doi:10.1155/2022/1786559 · Cited by 16 · see citing works
“Chaves et al. demonstrated that impairments in liver TR β signaling due to THRB gene mutations can lead to hepatic steatosis, indicating the influence of TH on lipid metabolism in the liver [22].”
Lifestyle Interventions to Tackle Cardiovascular Risk in Thyroid Hormone Signaling Disorders
Rodolfi, S., Rurale, G., Marelli, F., Persani, L., & Campi, I. (2025) · Nutrients · doi:10.3390/nu17132053 · Cited by 14 · see citing works
“Among the metabolic dysfunctions, we should also acknowledge that intramyocellular and intrahepatic lipid accumulation [123] cause MASLD [124], whereas data regarding insulin resistance in RTH β are conflicting [123,125]; nevertheless, diabetes and high fasting glucose were highly prevalent (11”
Resistance to Thyroid Hormones: A Case-Series Study
Cannarella, R., Musmeci, M., Garofalo, V., Timpanaro, T., Leone, G., Caruso, M., Maltese, P., Condorelli, R., la Vignera, S., & Calogero, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911268 · Cited by 11 · see citing works
“Therefore, THR influenced the accumulation of fat more that age and obesity [17].”
BackgroundCui, Y., Ru, M., Wang, Y.-J., Weng, L., Haji, R. A., Liang, H.-P., Zeng, Q.-J., Wei, Q., Xie, X., Yin, C., et al. (2024) · BMC Genomics · doi:10.1186/s12864-024-10270-w · Cited by 10 · see citing works
“Chaves et al. demonstrated that the nuclear receptor THRB plays a significant role in hepatic steatosis, highlighting the influence of thyroid hormone on lipid metabolism in the liver [34].”
BackgroundZhang, B., Zhao, M., Cong, X., Liu, C., Li, C.-F., Qiu, Y., Li, S., Chen, Y., Li, X.-X., & Li, P.-H. (2025) · Toxics · doi:10.3390/toxics13030214 · Cited by 9 · see citing works
“Research shows that the impaired signaling of thyroid hormone (TH) and thyroid hormone receptor beta (TR β ) in the liver can trigger hepatic steatosis [1].”
Domingues-Hajj, P. M. D. S., Gomes, P. M., Magalhães, P., & Maciel, L. M. Z. (2024) · Thyroid · doi:10.1089/thy.2024.0132 · Cited by 8 · see citing works
“14,15 That TC concentrations fall promptly after the administration of T3 in patients with RTH b 28 suggests resistance to the thyroid hormone action in the liver and a status of hypothyroidism in the organ.”
InfluentialLipoic acid in metabolic dysfunction-associated steatotic liver disease: a review
Liu, F., Lv, J.-J., Chen, Y., Wang, L., Liu, Z., & Li, X.-K. (2025) · Nutrition and Metabolism · doi:10.1186/s12986-025-00954-9 · Cited by 7 · see citing works
“For example, mutations in the thyroid hormone receptor beta (THRb) gene [83], the rs17618244 G > A β-Klotho (KLB) variant [84], germline hedgehog pathway [85], and polymerase I and transcript release factor [86], can also induce the occurrence of fatty liver.”
Oliveira, L. S. D., Kaserman, J., van der Spek, A. H., Lee, N. J., Undeutsch, H. J., Werder, R., Wilson, A. A., & Hollenberg, A. N. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102057 · Cited by 7 · see citing works
“Impairment of THR b 1 signaling may disrupt beta-oxidation of free FA, or disturb several metabolic processes including lipophagy, lipase activity, and mitochondrial function [40].”
Biochemical basis and therapeutic potential of mitochondrial uncoupling in cardiometabolic syndrome.
dos Santos, B. G., Brisnovali, N. F., & Goedeke, L. (2024) · Biochemical Journal · doi:10.1042/bcj20240005 · Cited by 5 · see citing works
Capuccio, S., Privitera, G., Scilletta, S., Rocca, F. L., Marco, M. D., Scicali, R., Pino, A. D., Piro, S., & Russello, M. (2026) · Liver international (Print) · doi:10.1111/liv.70431 · Cited by 4 · see citing works
Targeting THR-β for MASLD: Mechanisms and Drug Development
Hua, Y., Liu, Y., Xing, L.-J., Yu, X., Zheng, P.-Y., Yang, L., & Song, H.-Y. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s558221 · Cited by 4 · see citing works
“37 To elucidate the function of THR in lipid homeostasis, Araki et al created gene mutant mice with specific suppression of THR-α and THR-β.”
Moran, C., Martin-Grace, J., Lyons, G., Watson, L., Taylor, K., Oddy, S., Halsall, D., & Chatterjee, K. (2025) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/clinem/dgaf583 · Cited by 4 · see citing works
“Conversely, refractoriness to TH action in the liver, which expresses mainly TR β , may in part mediate the dyslipidemia [raised low-density lipoprotein cholesterol (LDL), triglycerides] and hepatic steatosis (9– 11) associated with RTH β .”
Davis, T. M. E., Davis, W., Moran, C., Lyons, G., Bryden, E., & Chatterjee, K. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf023 · Cited by 4
“It is characterized by elevated, circulating thyroid hormones with nonsuppressed TSH, dyslipidemia, and hepatic steatosis [2, 3], reflecting refractoriness to hormone action within the hypothalamic-pituitary-thyroid axis and liver, which are known to express mainly TR β .”
Teleken, J., Rosolen, A. P. F., Morari, J., Balbo, S., Ribeiro, R. A., & Bonfleur, M. L. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-025-04652-4 · Cited by 3 · see citing works
“Supporting this, individuals with mutations in THR-β, and thus resistant to T3, also show liver steatosis (Chaves et al. 2021).”
Mironova, M., Padmanabhan, K., Schneider, D., Schattenberg, J. M., & Loomba, R. S. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70888 · Cited by 2 · see citing works
“Resmetirom was granted accelerated approval by the United States Food and Drug Administration (FDA) in 2024 and a conditional marketing authorization by the European Medicines Agency (EMA) in 2025 [8, 11, 13].”
Xiong, W., Fan, H., Tang, J.-K., Yu, Q.-W., Xin, Z.-Y., Tang, T., Rao, X.-Y., Feng, L., Shi, Y.-M., Tong, X.-H., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1660437 · Cited by 2 · see citing works
Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease
Duntas, L. H., Polyzos, S. A., Gottwald-Hostalek, U., Urgatz, B., & Yen, P. M. (2025) · Endocrine · doi:10.1007/s12020-025-04451-0 · Cited by 2 · see citing works
“Notably, patients with mutations in the THRβ gene that reduce TH binding affinity also experience higher lev - els of hepatic steatosis and more liver fibrosis compared to controls [ 63].”
Self-citationLong, Y., Huang, F., Zhang, J., Zhang, J.-X., Cheng, R.-X., Zhu, L., Chen, Q.-L., Yang, D., Pan, X.-P., Yang, W.-F., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148996 · Cited by 2 · see citing works
Patil, R., Viswanatha, G., Andugulapati, S. B., Bojja, S., Pai, A., Satyanarayan, N. D., & Nandakumar, K. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118434 · Cited by 1 · see citing works
Thyroid hormones and metabolic flexibility: tissue-specific control of energy homeostasis
Cicatiello, A., Miro, C., Sagliocchi, S., Nappi, A., & Dentice, M. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1882438 · Cited by 1 · see citing works
“Yet, despite systemic thyrotoxicosis, patients exhibit reduced TH action in TR b - predominant tissues, including liver and pituitary, and often develop dyslipidemia, insulin resistance, and non-alcoholic fatty liver disease (Chaves et al., 2021).”
van der Spek, A. H., Ritter, M., Amano, I., de Oliveira, L. S., Kaserman, J., Cespedes, I. S., Vierling, T., Wilson, A. A., & Hollenberg, A. N. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000937 · Cited by 1 · see citing works
“[ 27 ] Thus, despite some clear clinical effects on glucose metabolism and insulin sensitivity, the systemic regulation of glucose by TH and the THR is inadequately and incompletely understood.”
Goyal, A., Gupta, R., & Singh, R. (2025) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2025-0150 · Cited by 1
Möller, L., Schörding, A.-K., Kaiser, F. J., Nöthen, M., Mack, E., & Neubauer, A. (2026) · Innere Medizin · doi:10.1007/s00108-026-02078-5
Management of Cardiovascular Morbidity Associated with Resistance to Thyroid Hormone Beta
Ponte, M., & Anselmo, J. (2026) · Endocrinology Insights · doi:10.1159/000550487
“In addition, RTHβ has also been associated with metabolic disturbances which may further increase cardiovascular risk [3, 12, 13].”
Self-citationChanges in transposable elements expression in male and female mice liver throughout aging
Hernández-Rojas, B., Murgas, P., & Riadi, G. (2026) · GeroScience · doi:10.1007/s11357-025-02065-y
- Authors
- Chaves, C., Bruinstroop, E., Refetoff, S., Yen, P. M., & Anselmo, J.
- Affiliations
- Hospital do Divino Espírito Santo (PT)
- Duke-NUS Medical School (SG)
- University of Chicago (US)
- Duke University (US)
- Corresponding author
- Anselmo, João
- Venue
- Thyroid®
- Publisher
- SAGE Publications
- Published
- 2021-07
- Volume
- 31
- Issue
- 7
- Pages
- 1127-1134
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- PMC
- PMC8290309
- OpenAlex
- W3113999992
- Cited by
- 55
- References
- 39
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 20 · 2023: 5 · 2022: 6 · 2021: 1
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-09-07)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Thyroid (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK015070)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- resistance to thyroid hormone beta, THRB gene, thyroid hormone receptor beta, hepatic steatosis, hepatic fat content, controlled attenuation parameter, transient elastography, free fatty acids, hepatic lipid metabolism, insulin resistance, non-alcoholic fatty liver disease, thyromimetics, first-degree relatives
- MeSH terms
- Adipose Tissue, Adolescent, Adult, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Middle Aged, Mutation, Thyroid Hormone Resistance Syndrome, Thyroid Hormone Receptors beta, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review